Clinical Trials Search
Clinical Trial 17971
Cancer Type: Thoracic
Study Type: Diagnostic
NCT#: NCT02194738
Phase: Phase III
Prinicipal Investigator: Jhanelle Gray
Study Title
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Summary
The purpose of this research study is to examine lung cancer patients' surgically removed tumors for certain genetic changes, and to possibly refer these patients to a treatment study with drugs that may specifically target tumors that have these genetic changes.
Objective
Screening Component: 1 Primary Objectives: 1.1 To centrally genotype resected lung adenocarcinomas for EGFR mutations and ALK rearrangements to facilitate accrual to randomized adjuvant studies. 1.2 To obtain clinically annotated tumor tissue and patient-matched non-malignant DNA from peripheral blood, as well as detailed epidemiologic and clinical follow-up data, to allow clinically annotated advanced genomic analyses in concert with the NCI Center for Cancer Genomics (CCG). 2 Secondary Objectives: 2.1 To characterize the natural history of EGFR and ALK wild-type lung cancers to allow subsequent development of targeted therapies against genotype-defined subpopulations in the adjuvant and recurrent settings. 2.2 To cross-validate local genotyping assays for EGFR and ALK with a central reference standard.
Therapies
Medications
Not Applicable ()
PATIENT PRE-REGISTRATION ELIGIBILITY CRITERIA:
If you are interested in learning more about clinical trials, our clinical trial navigators can discuss your options and recommend opportunities that may be suitable for you. Call 813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form.